Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency.[ Read More ]
The intrinsic value of one BNR stock under the base case scenario is HIDDEN Compared to the current market price of 3.75 USD, Burning Rock Biotech Limited is HIDDEN
Current Assets | 884 M |
Cash & Short-Term Investments | 629 M |
Receivables | 168 M |
Other Current Assets | 87.8 M |
Non-Current Assets | 156 M |
Long-Term Investments | 337 K |
PP&E | 144 M |
Other Non-Current Assets | 11.4 M |
Current Liabilities | 263 M |
Accounts Payable | 18.1 M |
Short-Term Debt | 8.63 M |
Other Current Liabilities | 237 M |
Non-Current Liabilities | 8.23 M |
Long-Term Debt | 3.69 M |
Other Non-Current Liabilities | 4.54 M |
Revenue | 537 M |
Cost Of Revenue | 174 M |
Gross Profit | 363 M |
Operating Expenses | 1.03 B |
Operating Income | -669 M |
Other Expenses | -15.6 M |
Net Income | -654 M |
Net Income | -654 M |
Depreciation & Amortization | 133 M |
Capital Expenditures | -9.38 M |
Stock-Based Compensation | 261 M |
Change in Working Capital | -52.2 M |
Others | -9.98 M |
Free Cash Flow | -265 M |
Date | Value | Insider | Amount | Avg Price |
---|